Browse by author
Lookup NU author(s): Dr Asima Mukhopadhyay, Professor Ruth Plummer, Dr Ahmed Elattar, Dr San Soo Hoo, Bisha Uzir, Professor Nicola CurtinORCiD, Professor Richard Edmondson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination-deficient (HRD) status on the clinicopathologic features, chemotherapy response, and survival outcomes of patients with EOCs. HR status was determined in primary cultures from ascitic fluid in 50 chemotherapy-naive patients by a functional RAD51 immunofluorescence assay and correlated with in vitro sensitivity to the PARP inhibitor (PARPi), rucaparib. All patients went on to receive platinum-based chemotherapy; platinum sensitivity, tumor progression, and overall survival were compared prospectively in HR-competent versus HRD patients. Compared with HR-competent patients, the HRD group was predominantly serous with a higher median CA125 at presentation. HRD was associated with higher ex vivo PARPi sensitivity and clinical platinum sensitivity. Median follow-up duration was 14 months; patients in the HRD group had lower tumor progression rates at 6 months, lower overall/disease-specific death rates at 12 months, and higher median survival. We therefore suggest that HRD as predicted by a functional RAD51 assay correlates with in vitro PARPi sensitivity, clinical platinum sensitivity, and improved survival outcome. Cancer Res; 72(22); 5675-82. (C) 2012 AACR.
Author(s): Elattar A; Mukhopadhyay A; Uzir B; Plummer ER; Curtin NJ; Edmondson RJ; Soohoo S; Quinn JE; McCluggage WG; Maxwell P; Aneke H
Publication type: Article
Publication status: Published
Journal: Cancer Research
Year: 2012
Volume: 72
Issue: 22
Pages: 5675-5682
Print publication date: 11/10/2012
ISSN (print): 0008-5472
ISSN (electronic): 1538-7445
Publisher: American Association for Cancer Research
URL: http://dx.doi.org/10.1158/0008-5472.CAN-12-0324
DOI: 10.1158/0008-5472.CAN-12-0324
Altmetrics provided by Altmetric
